Precision Target Discovery for Migraine: An Integrated GWAS-eQTL-PheWAS Pipeline
Molecules · 2025
DOI: 10.3390/molecules30193921 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Xianting Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-So…. Hauptthemen laut MEDLINE: Genome-Wide Association Study, Migraine Disorders, Quantitative Trait Loci. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Scholarships Foundation, Sichuan University Research Funds for Basic Medicine Research and University of Macau, the Traditional Chinese Medicine Science and Technology Industry Innovation Team of Sichuan Province and the Multi‑ dimensional Evaluation and Product Developm….
Abstract (Originalsprache)
Migraine is a complex neurological disorder that severely compromises quality of life. Current therapies remain inadequate, creating an urgent need for precision medicine approaches. To bridge this gap, we integrated genome-wide association studies (GWASs) and multi-tissue expression quantitative trait loci (eQTL) data. Using Mendelian randomization (SMR/HEIDI) to identify putatively causal genes, followed by colocalization analysis, protein–protein interaction networks, and gene enrichment, we prioritized druggable targets. Phenome-wide association studies (PheWASs) further assessed their potential safety profiles. We identified 31 migraine-associated genes in whole blood, 20 in brain tissue, and 9 genes shared by both whole blood and brain regions. Among 13 druggable genes identified from the DGIdb and supporting literature, 10 passed colocalization validation. Eight genes (TGFB3, CHRNB1, BACE2, THRA, NCOR2, NR1D1, CHD4, REV3L) showed interactions with known drug targets, enabling the computational prediction of 41 potential repurposable drugs. Based on target druggability, PPI (protein–protein interaction) and favorable PheWAS profiles, NR1D1, THRA, NCOR2, and CHD4 are prioritized for drug development. Additionally, MICU1, UFL1, LY6G5C, and PPP1CC emerged as novel pathophysiological factors. This study establishes a multi-omics framework for precision migraine therapy, translating genetic insights into clinically actionable targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, Sichuan Research Center for Drug Precision Industrial Tech…
- Faculty of Health Sciences, University of Macau, Macau SAR, China.
ORCID-Profile: Xianting Liu, Ming Hu, Fu Peng
Förderung
- State Scholarships Foundation
- Sichuan University Research Funds for Basic Medicine Research and University of Macau
- the Traditional Chinese Medicine Science and Technology Industry Innovation Team of Sichuan Province and the Multi‑ dimensional Evaluation and Product Developm…
- Fundamental Research Funds for the Central Universities
- Sichuan University Research Funds for Graduate Education and Teaching Reform
Zitieren
APA
Liu, X., Liu, Q., Zhu, H., Zhou, X., Li, X., Hu, M., Peng, F., Ji, J., & Yang, S. (2025). Precision Target Discovery for Migraine: An Integrated GWAS-eQTL-PheWAS Pipeline. Molecules. https://doi.org/10.3390/molecules30193921
Vancouver
Liu X, Liu Q, Zhu H, Zhou X, Li X, Hu M, et al. Precision Target Discovery for Migraine: An Integrated GWAS-eQTL-PheWAS Pipeline. Molecules. 2025. doi:10.3390/molecules30193921
BibTeX
@article{Liu2025,
author = {Liu, Xianting and Liu, Qingming and Zhu, Haoning and Zhou, Xiao and Li, Xinyao and Hu, Ming and Peng, Fu and Ji, Jianguang and Yang, Shu},
title = {Precision Target Discovery for Migraine: An Integrated GWAS-eQTL-PheWAS Pipeline},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30193921}
}
EUVIMED